EBR Systems is girding for US FDA approval of its novel heart lead in April and commercialisation by the end of the year.

CMS has accepted EBR's WiSE cardiac resynchronisation therapy (CRT) system into the fast-track TCET reimbursement pathway. ..

Elon Musk didn’t provide any details about the latest patient to get an implant from his brain-computer interface company, ...

Having raised AUD 53 million in equity funding in fiscal 2023, Polynovo is in a comfortable financial position with net cash of AUD 43 million as of June 2024. We do not expect Polynovo will need to ...